The DBV Technologies has developed the peanut patch, which is looking promising in the treatment of peanut allergies and can protect from accidental ingestion or exposure.

According to Gizmodo, a  Viaskin peanut patch, made by DBV technologies, shows amazing results. Peanut allergies are a very common form of allergies and are mostly found in Americans and Britishers.  It occurs due to intake of peanuts, which are not supported by the body, resulted itchy skin, nausea, tingling sensation, a runny or congested nose and Anaphylaxis according to ACAAI. It is also be said that there is no cure of this allergy. The only way is to get rid of peanuts to avoid this allergy otherwise it can creates serious problems.  

There are several types of allergies of which there is no cure, but this patch delivers proteins from peanut through the skin and this process is called epicutaneous immunotherapy (EPIT). It was conducted by the Consortium of Food Allergy Research (CoFAR) and includes various participants who came forward to try this patch to support it.

These participants, who already had this allergy, were chosen to apply this patch. They all were aged 4 to 25. Their patches include high as well as low doses according to the volunteers.  All the participants were given the fresh patches of the peanut every day to get the good results.   

After a year, the results are amazing.. The kids showed better results, as kids immune system works better than the adults.  People showed serious response to this patch, as it helped in increasing the tolerance power in them.  Although it is not approved by US food and drug administration, but there is a possibility that it can be a good heals for this allergy. 

This clinical test will be continued for two years more years to get complete effective results. reseachers are trying to get more volunteers for this, so as their condition can be reviewed properly.  The researchers will focus on this Viaskin to make it a proper success and we never know it might be commercially available soon.